Early Prediction and Warning for Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy

NCT06282796 · tracked via the Priya Life Science China tracker

Sponsor

First Hospital of China Medical University

Phase

Observational

Started

2024-01-01

Last updated

2024-02-28

Condition(s) studied

Breast Cancer

Investigational drug(s) / intervention(s)

Echocardiography

Echocardiography: Two-dimensional, color Doppler, spectral Doppler, tissue Doppler and three-dimensional echocardiographic image recordings will be taken using a Philips Epiq 7C echocardiography device and X5-1 probe. Conventional parameters, additional parameters, and strain analyzes will be performed by TomTec AutoStrain Suite Software

Study summary

This multicenter clinical study aims to build an intelligent and accurate diagnosis and dynamic prediction and early warning model of cardiotoxicity due to anthracycline-based breast cancer chemotherapy, clarify the value of the early warning model in guiding the targeted prevention of myocardial protection, providing an important theoretical basis for reducing the mortality rate of breast cancer and improving the prognosis.

Eligibility

Sex

FEMALE

Min age

18 Years

Max age

80 Years

Healthy volunteers

Inclusion Criteria: * Age ≥18 years * Histologically or cytopathological confirmed stage I-III HER2+ breast cancer, scheduled to receive consecutive anthracycline chemotherapy or subsequent sequential trastuzumab targeted therapy * LVEF≥53% before chemotherapy Exclusion Criteria: * life expectancy ≤12 months * Participating in other ongoing oncology clinical trials * Prior treatment with anthracyclines or chest radiation therapy * Pregnant or lactating women * Ultrasound images of the heart are of very poor quality

Primary outcome measure(s)

Left ventricular ejection fraction(unit: %) in all breast cancer patients treated with anthracycline-based chemotherapy. — 1 day after admission
To Evaluate the changes of cardiac systolic function in all breast cancer patients treated with anthracycline-based chemotherapy.

Trial sites (5)

Facility	City	Region	Status
Fujian Cancer Hospital	Fuzhou	Fujian	Recruiting
Dalian Friendship Hospital	Dalian	Liaoning	Recruiting
Dalian Municipal Central Hospital	Dalian	Liaoning	Recruiting
Liaoning Cancer Hospital & Institute	Shenyang	Liaoning	Recruiting
The Third People's Hospital Of Chengdu	Chengdu	Sichuan	Recruiting

More First Hospital of China Medical University trials in China

LLM-CoManage: Large Language Model-Enabled Co-Management of Hypertension, Diabetes, and Dyslipidemia Active, not recruiting

Application of 68Ga-NODAGA-SNA006 Positron Emission Tomography/Computed Tomography (PET/CT) in Tumors Active, not recruiting

Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque Psoriasis Recruiting

Randomized Controlled Clinical Trial of Hyperthermia and Hydrogen Peroxide 3% in the Treatment of Cutaneous Warts Recruiting

A Multicenter Study on the Normal Reference Range and Clinical Significance of the Right Atrioventricular Coupling Index Assessed by Artificial Intelligence-Based Three-Dimensional Echocardiography Starting soon

Other trials for the same condition

A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors Recruiting

ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC Active, not recruiting

A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer Recruiting

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03) Recruiting

Myeloprotection With Trilaciclib in Pan-cancer Population Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06282796 on ClinicalTrials.gov ↗ ← All trials in China